T

Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM

Watchlist Manager
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Watchlist
Price: 3 794.4 INR 0.81% Market Closed
Market Cap: 1.3T INR

Torrent Pharmaceuticals Ltd
Pre-Tax Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Torrent Pharmaceuticals Ltd
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Pre-Tax Income
₹28.8B
CAGR 3-Years
32%
CAGR 5-Years
16%
CAGR 10-Years
4%
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Pre-Tax Income
₹75.3B
CAGR 3-Years
20%
CAGR 5-Years
30%
CAGR 10-Years
15%
Cipla Ltd
NSE:CIPLA
Pre-Tax Income
₹70.4B
CAGR 3-Years
25%
CAGR 5-Years
22%
CAGR 10-Years
12%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Pre-Tax Income
₹140.7B
CAGR 3-Years
40%
CAGR 5-Years
53%
CAGR 10-Years
11%
Zydus Lifesciences Ltd
NSE:ZYDUSLIFE
Pre-Tax Income
₹64.6B
CAGR 3-Years
32%
CAGR 5-Years
26%
CAGR 10-Years
13%
Lupin Ltd
NSE:LUPIN
Pre-Tax Income
₹53.9B
CAGR 3-Years
164%
CAGR 5-Years
39%
CAGR 10-Years
6%
No Stocks Found

Torrent Pharmaceuticals Ltd
Glance View

In the bustling realm of Indian pharmaceuticals, Torrent Pharmaceuticals Ltd. has carved out a notable niche, emerging from the industrious land of Gujarat. Founded in 1959, this company has transformed from a modest player to a major force in the industry, traversing the complexities of pharmaceutical manufacturing and global distribution. At its core, Torrent Pharmaceuticals is driven by a commitment to healthcare innovation and therapeutic excellence. The company systematically engages in developing, manufacturing, and marketing a wide array of generic pharmaceutical products primarily targeting cardiovascular, central nervous system, gastro-intestinal, anti-infective, and anti-diabetic therapeutic categories. This diverse product portfolio positions Torrent not just as a provider of remedies but as a critical player in improving health outcomes across numerous demographics and geographies. Torrent Pharmaceuticals operates on a robust business model that effectively integrates research, development, and widespread distribution to generate revenue. The company channels significant resources into its R&D capabilities, perpetually expanding its pipeline to introduce more effective and affordable medications. This ongoing innovation supports their competitive edge while fortifying their catalog of offerings. Additionally, Torrent's strategic alliances and acquisitions—most notably, the key acquisition of Elder Pharmaceuticals' branded domestic formulations business in India—have further catapulted its market presence both domestically and internationally. By leveraging its extensive marketing network and manufacturing capabilities compliant with international standards, Torrent not only bankrolls its growth through product sales but also ensures global reach, cementing its role as a pivotal component of the healthcare landscape.

TORNTPHARM Intrinsic Value
2 399.04 INR
Overvaluation 37%
Intrinsic Value
Price
T

See Also

What is Torrent Pharmaceuticals Ltd's Pre-Tax Income?
Pre-Tax Income
28.8B INR

Based on the financial report for Sep 30, 2025, Torrent Pharmaceuticals Ltd's Pre-Tax Income amounts to 28.8B INR.

What is Torrent Pharmaceuticals Ltd's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 10Y
4%

Over the last year, the Pre-Tax Income growth was 12%. The average annual Pre-Tax Income growth rates for Torrent Pharmaceuticals Ltd have been 32% over the past three years , 16% over the past five years , and 4% over the past ten years .

Back to Top